Here's some of what is coming soon to NeurologyLive® this week.
|Videos|July 22, 2021
Evolving Rehabilitation Strategies for Multiple Sclerosis
Ahmed Obeidat, MD, PhD; Francois Bethoux, MD; and Nicholas C. Ketchum, MD, discuss recent advancements and future directions in rehabilitation strategies for multiple sclerosis.
Advertisement
————————————
Panelists
- Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin - Nicholas C. Ketchum, MD
Residency Program Director, Department of Physical Medicine and Rehabilitation, Medical College of Wisconsin - Francois Bethoux, MD
Director, Rehabilitation Services, Mellen Center for MS Treatment and Research, Cleveland Clinic
Key Learning Objectives
- Gait and ambulation in multiple sclerosis
- Spasticity and its management in multiple sclerosis
- Technology and rehabilitation in multiple sclerosis
- Traditional versus nontraditional approaches of rehabilitation in multiple sclerosis
Advertisement
Related to this article
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
The positive opinion for intravenous ocrelizumab was supported by phase 3 OPERETTA 2 findings demonstrating noninferior relapse control and superior suppression of MRI-detected brain lesions compared with fingolimod in pediatric patients with relapsing MS.
An ACT–based group intervention did not significantly improve resilience at 3 months in patients with MS but was associated with improvements in anxiety, well-being, psychological flexibility, and health-related quality of life.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
A recent MS cohort study suggests that higher EBV nuclear antigen 1 antibody levels are associated with a lower risk of confirmed disability worsening, particularly among patients carrying both HLA-A02:01 and HLA-DRB115:01.
The FDA clearance allows AbelZeta to study bispecific CAR T-cell therapy C-CAR168 in refractory progressive multiple sclerosis.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
SHIELD Trial Advances Combination Antiviral for Long COVID
3
Gefurulimab Cuts Hospitalizations, Sustains Response in Phase 3 PREVAIL Trial of Myasthenia Gravis
4